Omya has announced a new bone-health dietary supplement product including its Omyapharma and Omyapure calcium-carbonate ingredients.
Image provided by Omya.
Omya (Oftringen, Switzerland) has released a new bone-health supplement product feature calcium carbonate, vitamin K2, and vitamin D3. The combination is meant to offer enhanced absorption of calcium and ensure consumers reach the EU’s recommended daily allowance of calcium.
The new formulation features two of Omya’s branded calcium-carbonate ingredients: Omyapure 35 – OG, the active calcium-carbonate ingredient, and Omyapharm 500 – OG, an excipient that provides several formulation advantages.
“As an efficient carrier for multiple substances, [Omyapharm] allows a high loading capacity of active ingredients,” Omya explains in the product announcement. “Its particles are characterized by an external lamellae structure and an internal network of interconnected pores. This structure facilitates the production of tablets that uniquely feature both high porosity and maximum levels of hardness.”
Additionally, the product includes vitamin K2 and vitamin D3, both of which are known to improve calcium absorption rates, Omya notes.
“Vitamin K2 acts as an activator of proteins which are responsible for utilizing and storing the calcium,” Omya says. “Vitamin D3 supports the bioavailability of calcium by regulating the calcium and phosphorus homeostasis, and hence facilitating the absorption of this mineral.”
The firm recently debuted the formula in easy-to-swallow tablet form at the recent Health Ingredients Europe trade show in Germany, but it notes that other dosage forms are possible, including orally disintegrating tablets or orally disintegrating granules.
Read more:
Bone Health Ingredients Stand Tall in New Research
NEM Eggshell Membrane May Improve Inflammation, Arthritis Markers, Animal Study Suggests
2017 Ingredient Trends to Watch for Food, Drinks, and Dietary Supplements: Vitamin B12
Magnesium L-threonate, Magtein, earns novel food authorization in the European Union
December 19th 2024According to the announcement, the authorization is also exclusive to AIDP and its partner company and licensee, ThreoTech, meaning that they are the only parties that can market magnesium L-threonate in the EU for a period of five years.
Survey finds a lack of enthusiasm about AI technology among food and beverage consumers
December 12th 2024The survey, commissioned by Ingredient Communications and conducted by SurveyGoo, found that 83% of respondent agreed that companies should declare on product labels when a product has been designed or manufactured with the assistance of AI technology.
Kelker Pharma to launch nutritional support system for GLP-1 medication users that features TriBsyn
December 11th 2024B&D Nutritional Ingredients Inc., an exclusive distribution partner of CarnoSyn Brands and Natural Alternatives International Inc., announced that its customer, Kelker Pharma, will be launching the “first science-backed nutritional support system” for GLP-1 medication users, called Nutrilinq Genesis.